指南与共识儿科与产科急症消化、代谢与肾脏急症

妊娠期、儿科、免疫功能低下及过敏或既往SARS-CoV-2感染者的COVID-19疫苗接种:当前建议与上市前后疫苗效力及安全性证据概述

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
指南 / 共识 · Drug Saf · 2021-11-05
一句话结论本文综述了妊娠、儿童、免疫功能低下及过敏或既往感染者接种COVID-19疫苗的上市前后证据及科学学会与监管机构建议。

本文为叙述性综述,针对欧洲药品管理局紧急使用或有条件批准的四种COVID-19疫苗(Comirnaty、COVID-19 Vaccine Janssen、Spikevax、Vaxzevria),聚焦妊娠及哺乳期女性、儿童/青少年、免疫功能低下者、有过敏史或既往SARS-CoV-2感染者等特殊人群。文章批判性概述了这些人群中疫苗潜在获益与风险的上市前及上市后证据,并汇总了科学学会和监管机构对上述疫苗接种类别的初级预防建议。

要点

  • 四种疫苗为Comirnaty、COVID-19 Vaccine Janssen、Spikevax和Vaxzevria,均获欧洲药品管理局紧急使用授权或有条件批准。
  • 一般人群中获益-风险 profile 被证明大体有利,但特殊人群(孕妇、哺乳期、儿童/青少年、免疫功能低下、过敏或既往感染者)证据仍有限。
  • 本文综述了上述特殊人群的上市前和上市后证据,并汇总科学学会与监管机构的建议。

适用人群与场景

  • 妊娠及哺乳期女性
  • 儿童/青少年
  • 免疫功能低下者
  • 有过敏史或既往SARS-CoV-2感染者

研究设计与关键结果

  • 本文为叙述性综述,批判性概述了已上市COVID-19疫苗在妊娠及哺乳期女性、儿童/青少年、免疫功能低下者、有过敏史或既往SARS-CoV-2感染者中的潜在获益与风险的上市前及上市后证据,并汇总了科学学会和监管机构对上述疫苗接种类别的COVID-19初级预防建议。

证据类型、等级与局限

  • 证据类型:叙述性综述;原文指出特殊人群证据仍有限。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 原文未据此给出推荐

指南或共识出处

  • 欧洲药品管理局(European Medicines Agency)对Comirnaty、COVID-19 Vaccine Janssen、Spikevax、Vaxzevria的紧急使用授权或有条件批准
  • 科学学会和监管机构关于上述疫苗接种类别COVID-19初级预防的建议(原文汇总,未列具体名称)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit-risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overview pre- and post-marketing evidence on the potential benefits and risks of marketed COVID-19 vaccines in the above-mentioned special cohorts. In addition, we summarise the recommendations of the scientific societies and regulatory agencies about COVID-19 primary prevention in the same vaccinee categories.

来源:Drug Saf,查看原文。版权归原作者所有。

参考来源

  1. Luxi N, Giovanazzi A, Capuano A, et al. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Saf. 2021. PMID: 34739716. doi:10.1007/s40264-021-01131-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。